These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23645657)

  • 21. Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
    Hoy SM
    Drugs; 2012 Oct; 72(14):1929-50. PubMed ID: 22950536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Renal infiltrate by a plasmocytoïd chronic B lymphocytic leukaemia and renal failure: a rare occurrence in nephropathology. A case report and review of the literature].
    Aymard B; Beghoura R; Molina TJ
    Nephrol Ther; 2011 Nov; 7(6):479-87. PubMed ID: 21439927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Elefante A; Czuczman MS
    Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
    Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
    Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report.
    Gueli A; Gottardi D; Hu H; Ricca I; De Crescenzo A; Tarella C
    Blood Transfus; 2013 Apr; 11(2):311-4. PubMed ID: 23399352
    [No Abstract]   [Full Text] [Related]  

  • 26. Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: a survey from Tyrolean hospitals.
    Waldthaler C; Stauder R; Schnallinger M; Schreieck S; Hager J; Oexle H; Zangerl G; Verdorfer I; Zabernigg A; Gastl G; Fiegl M
    Wien Klin Wochenschr; 2011 May; 123(9-10):269-75. PubMed ID: 21479652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia.
    Weide R; Mergenthaler U; Friesenhahn V; Kleboth K; Heymanns J; Thomalla J; Köppler H
    Leuk Lymphoma; 2009 Sep; 50(9):1468-74. PubMed ID: 21049589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group.
    Cuneo A; Marchetti M; Barosi G; Billio A; Brugiatelli M; Ciolli S; Laurenti L; Mauro FR; Molica S; Montillo M; Zinzani P; Tura S
    Leuk Res; 2014 Nov; 38(11):1269-77. PubMed ID: 25063524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.
    Weide R; Heymanns J; Gores A; Köppler H
    Leuk Lymphoma; 2002 Feb; 43(2):327-31. PubMed ID: 11999564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chronic lymphocytic leukemia].
    Aoki S
    Rinsho Ketsueki; 2014 Feb; 55(2):213-22. PubMed ID: 24598189
    [No Abstract]   [Full Text] [Related]  

  • 31. Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study.
    Weide R; Pandorf A; Heymanns J; Köppler H
    Leuk Lymphoma; 2004 Dec; 45(12):2445-9. PubMed ID: 15621757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Direct Antiglobulin Test Negativity after Bendamustine and Rituximab Treatment in Chronic Lymphocytic Leukemia: Two Cases.
    Eren R; Suyanı E
    Turk J Haematol; 2018 Nov; 35(4):312-313. PubMed ID: 29983407
    [No Abstract]   [Full Text] [Related]  

  • 33. Bendamustine as monotherapy and in combination regimens for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma: a retrospective analysis.
    Hus I; Jawniak D; Gorska-Kosicka M; Butrym A; Dzietczenia J; Wrobel T; Grzegorz M; Lech-Maranda E; Warzocha K; Waszczuk-Gajda A; Jedrzejczak WW; Krawczyk-Kulis M; Kyrcz-Krzemien S; Poplawska L; Walewski J; Dmoszynska A
    Chemotherapy; 2013; 59(4):280-9. PubMed ID: 24457828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Alleviated anemia by bendamustine in cold agglutinin disease associated with small lymphocytic lymphoma].
    Kuno M; Inoue A; Aimoto M; Nakao T; Kameda K; Yoshida M; Kanashima H; Hirai M; Yamane T
    Rinsho Ketsueki; 2015 Feb; 56(2):204-9. PubMed ID: 25765801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treanda approved for chronic lymphocytic leukemia.
    Traynor K
    Am J Health Syst Pharm; 2008 May; 65(9):793. PubMed ID: 18436722
    [No Abstract]   [Full Text] [Related]  

  • 36. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.
    Ninkovic M; Fiegl M; Mian M; Mondello P; Kocher F; Waldthaler C; Verdorfer I; Steurer M; Gastl G; Pircher A
    Anticancer Res; 2015 Sep; 35(9):5129-39. PubMed ID: 26254418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab.
    García Muñoz R; Izquierdo-Gil A; Muñoz A; Roldan-Galiacho V; Rabasa P; Panizo C
    Ann Hematol; 2014 Nov; 93(11):1879-87. PubMed ID: 24951124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
    Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
    Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
    Chang JE; Havighurst T; Kim K; Eickhoff J; Traynor AM; Kirby-Slimp R; Volk LM; Werndli J; Go RS; Weiss M; Blank J; Kahl BS
    Br J Haematol; 2016 Apr; 173(2):283-91. PubMed ID: 26913697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bendamustine in CLL: How quickly will today's consensus become tomorrow's memory?
    Cheson BD
    Leuk Res; 2014 Nov; 38(11):1267-8. PubMed ID: 25260826
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.